Delivers RT PCR results in 40 minutes from sample to report without any RNA Extraction kit & its instrument.
First of its kind product “Made in India”, this kit with coverage of 3 target genes specific to SARS-CoV-2
Validated at ICMR centre with 100% sensitivity and specificity
Received DCGI and European CE-IVD approval
Genes2Me, a leading IVD Manufacturer and Genetic diagnostics Company, recently launched its brand new product RT- Direct Multiplex RTPCR kit for COVID-19. First of its kind “Made in India” product, this kit is based on Gold standard RTPCR method with coverage of 3 target genes specific to SARS-COV-2 along with IC, which is much advanced than all others having 1 or 2 target genes. This greatly increases the sensitivity of the RTPCR test to detect samples with different mutations/variants as this kit targets 3 different Sars-cov-2 target regions.
RT- Direct Multiplex RTPCR kit for COVID-19
Validated at ICMR approved Centre with 100% sensitivity and specificity, this newly launched kit can deliver results in just 40 minutes. RT-Direct test protocol does not require any manual extraction step or automated instrument, making it faster and easier to deliver results. It will also increase the throughput of any testing lab by 3 fold compared to the normal RTPCR test protocol time of 120-150 minutes.Without needing any additional device, timing of RT-Direct RTPCR kit test results have been reduced to just 40 Minutes. The Company has also received DCGI approval for this Kit.
While talking about the benefits of the new product, Mr. Neeraj Gupta, Founder and CEO, Genes2Me said, “The process of RNA extraction have been a crucial step till now in RT PCR testing protocol for COVID-19 which affects the reporting time, results and cost. Our newly launched RTPCR kit will not only reduce the turnaround time by 3 times but also save huge cost of extraction kit and machine which would eventually make COVID test more affordable in our country. Further he added that the company innovated proprietary enzyme is one of the world’s fastest & efficient, that helps in reducing the RTPCR time by half than standard other enzymes used in all other kits. This is main reason why we are able to reduce the reaction time in 40 mins with 100% sensitivity.”
“With the use of our RT- Direct Multiplex RTPCR kit for COVID-19, all the diagnostic entities will be able to deliver the results in shortest time. Thus, in case of the next COVID wave, the kit will help in reducing the burden on the diagnostic industry in delivering fast and accurate results. The test kit is also compatible with commonly available RT PCR devices in the market,” he added.
Since the pandemic has started, Genes2Me has been coming up with a variety of innovative solutions to combat the challenge posed by COVID-19. Genes2Me stepped into manufacturing the highest quality ICMR Validated and CE-IVD certified Molecular IVD kits for COVID-19 testing. It is now established as one of the leading manufacturers of IVD kits for COVID-19 testing and has supplied more than 50 million tests till now.
These advanced kits will be immediately applied in many labs across the country including Genes2Me own clinical diagnostic laboratory. We will be able to do reporting for patient samples in less than 60 mins. The kit is now easily available in India from second week of November 2021 and for international market it will be available after a global launch at Medica, event on 15th November at Messe Dusseldorf, Germany.
About Genes2Me Pvt. Ltd.
Founded in 2016 by Mr. Neeraj Gupta and Ms. Ritu Gupta, Genes2Me is a Genomics-focused diagnostic company with an aim to continuously develop unique & Innovative IVD Genetic solutions to enhance global health even in resource-limited areas. Through its broad range of Genetic tests, Genes2Me have been serving Clinicians and Individuals across India to understand Complex Genetics Disorders and susceptibility to various health conditions. Company has been able to deliver Innovative Genetic Testing solutions as a manufacturer of IVD kits and also providing genetic testing services in the segments of Personalized Health, Mother and Child Care, Oncology & Infectious Diseases.
This Press Release has not been vetted or endorsed by The Eastern Herald’s editorial staff.